BWL
TLX

Bogart Wealth LLC’s Telix Pharmaceuticals TLX Stock Holding History

Bogart Wealth LLC’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300 Buy
+26
New +$265 ﹤0.01% 1872

Other funds holding TLX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Bogart Wealth LLC's TLX Position: Q2 2026 in Review

Bogart Wealth LLC opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 26 shares worth $300. The stake represents ﹤0.01% of the portfolio and ranks #1872 among its holdings.

9 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Bogart Wealth LLC held 26 shares of Telix Pharmaceuticals worth $300 as of Q2 2026.
  • Telix Pharmaceuticals was a new Bogart Wealth LLC position in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #1872 holding.
  • 9 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.